第二次造血干细胞移植的进展
Sijia Yan1, Xiaojian Zhu1, Yi Xiao1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in immunology
|July 24, 2024
概括
第二次造血干细胞移植 (HSCT2) 为最初的HSCT后复发性血液病患者提供了治疗选择. 供体选择不会影响HSCT2疗效,但复发风险仍然很大.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 移植医学 移植医学
背景情况:
- 造血干细胞移植 (HSCT) 是恶性血液病的基石疗法.
- 在HSCT后疾病复发需要探索替代治疗策略.
研究的目的:
- 评估第二次造血干细胞移植 (HSCT2) 的疗效和影响因素,在 HSCT1.1.后复发的患者中.
- 确定HSCT2成功的关键决定因素和未来研究领域.
主要方法:
- 审查分析HSCT2可行性和结果的现有研究.
- 确定与HSCT2疗效相关的预后因素.
主要成果:
- 诸如造血细胞移植并发症指数,HSCT1后缓解持续时间,慢性移植对宿主疾病和HSCT2前疾病状态等因素影响HSCT2结果.
- 发现对HSCT2的捐赠者选择没有显著影响移植疗效.
结论:
- 对于复发性血液性恶性瘤的患者来说,HSCT2是一种可行的选择.
- 进一步的研究对于改善HSCT2后复发患者的治疗策略和治疗结果至关重要,因为二次复发的预后不佳.
相关概念视频
Bone Marrow Sampling and Transplants
318
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
318
Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Hematopoiesis
5.2K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.2K


